Market Place
Sourcing Support
Neurocrine to Present Two-Year Crenessity Data at ENDO 2026
03 Jun 2026 //
PR NEWSWIRE
Neurocrine Biosciences Completes Soleno Therapeutics Acquisition
18 May 2026 //
PR NEWSWIRE
Neurocrine Publishes Glucocorticoid Dose Reduction Guidelines
06 May 2026 //
PR NEWSWIRE
Neurocrine Biosciences Shows Durable Hormone Control
01 May 2026 //
PR NEWSWIRE
Neurocrine Presents Two-Year CRENESSITY Data in CAH Adults
23 Apr 2026 //
PR NEWSWIRE
Neurocrine Shows 1-Year CRENESSITY® Results at ENDO 2025
14 Jul 2025 //
PR NEWSWIRE
Neurocrine Shares CAHtalyst™ 1-Year Data at ENDO 2025
14 Jul 2025 //
PR NEWSWIRE
Neurocrine: Crenessit™ Data in Classic CAH Patients
15 May 2025 //
PR NEWSWIRE
Neurocrine Bio Announces Crenessity Availability for CAH Patients
20 Dec 2024 //
PR NEWSWIRE
US FDA approves Neurocrine Biosciences` genetic disorder drug
14 Dec 2024 //
REUTERS
FDA Roundup: December 13, 2024
13 Dec 2024 //
PR NEWSWIRE
FDA Grants Priority Review For Neurocrine`s Crinecerfont In CAH
01 Jul 2024 //
PR NEWSWIRE
Neurocrine Receives Breakthrough Therapy Designation from FDA for Crinecerfont
05 Dec 2023 //
PR NEWSWIRE
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont
05 Oct 2023 //
PR NEWSWIRE
Neurocrine`s crinecerfont succeeds in congenital adrenal hyperplasia trial
13 Sep 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.